Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvocidib - Sanofi-aventis/Sumitomo Pharma America

Next Previous
X
Search
Drug Profile

Alvocidib - Sanofi-aventis/Sumitomo Pharma America

Alternative Names: Alvocidib hydrochloride; DSP-2033; Flavopiridol; Flavopiridol hydrochloride; HL-275; HMR 1275; IND 46211; L-86-8275; MDL-107826A; NSC 649890

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AbbVie; National Cancer Institute (USA); Sumitomo Pharma America; Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Chlorinated hydrocarbons; Flavonoids; Ketones; Piperidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Germ cell and embryonal neoplasms; Germ cell cancer; HIV infections; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 10 May 2023 3781050- Intro, KDM updated, dev line forwarded to disconiued
  • 28 Apr 2023 Discontinued - Phase-III for Chronic lymphocytic leukaemia (Second-line therapy or greater) in European Union (IV)
  • 28 Apr 2023 Discontinued - Phase-III for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top